Key result
Comprehensive genetic analysis of 6,605 individuals identified pathogenic secondary findings in cardiovascular disease genes in 1%, including 0.2% specifically in ARVC genes.
Why the study?
Although genetic secondary findings in actionable ARVC genes offer early diagnosis to prevent sudden cardiac death, variant interpretation and the decision to return findings remain challenging.
What is the prevalence of actionable secondary findings in ARVC genes among individuals undergoing comprehensive genetic analysis?
Observational (n=6,605)
What is the prevalence of actionable secondary findings in ARVC genes among individuals undergoing comprehensive genetic analysis?
Pathogenic secondary findings in ARVC genes are rare (0.2%) but require rigorous clinical and laboratory evaluation and interdisciplinary genetic counseling before being returned to patients.
Rigorous variant classification remains essential before returning ARVC SF; leaves open optimal counseling strategies for low-prevalence findings.
BACKGROUND: Comprehensive genetic analysis yields in a higher diagnostic rate but also in a higher number of secondary findings (SF). American College of Medical Genetics and Genomics (ACMG) published a list of 59 actionable genes for which disease causing sequence variants are recommended to be reported as SF including 27 genes linked to inherited cardiovascular disease (CVD) such as arrhythmia syndromes, cardiomyopathies and vascular and connective tissue disorders. One of the selected conditions represented in the actionable gene list is the arrhythmogenic right ventricle cardiomyopathy (ARVC), an inherited heart muscle disease with a particularly high risk of sudden cardiac death (SCD). Since clinical symptoms are frequently absent before SCD, a genetic finding is a promising option for early diagnosis and possible intervention. However, the variant interpretation and the decision to return a SF is still challenging. METHODS: and compared our findings with the population-based genome Aggregation Database (gnomAD) and ARVC-afflicted individuals listed in ClinVar and ARVC database. RESULTS: 1% (69/6,605) of tested individuals carried pathogenic SF in one of the 27 genes linked to CVD, of them 13 individuals (0.2%) carried a pathogenic SF in a ARVC gene. Overall, 582 rare variants were identified in all five ARVC genes, 96% of the variants were missense variants and 4% putative LoF variants (pLoF): frameshift, start/stop-gain/loss, splice-site. Finally, we selected 13 of the 24 pLoF variants as pathogenic SF by careful data interpretation. CONCLUSIONS: Since SF in actionable ARVC genes can allow early detection and prevention of disease and SCD, detected variant must undergo rigorous clinical and laboratory evaluation before it can be described as pathogenic and returned to patients. Returning a SF to a patient should be interdisciplinary, it needs genetic counselling and clinicians experienced in inherited heart disease.
No takes yet. Share an insight, caveat, or question.
Abicht et al. (2021) conducted an observational in Arrhythmogenic right ventricle cardiomyopathy (ARVC) and inherited cardiovascular disease (n=6,605). Comprehensive genetic analysis for secondary findings was evaluated on Pathogenic secondary findings in genes linked to cardiovascular disease and ARVC. Comprehensive genetic analysis of 6,605 individuals identified pathogenic secondary findings in cardiovascular disease genes in 1%, including 0.2% specifically in ARVC genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: